SS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer SS Innovations International, Inc. appoints seasoned executive Milan Rao to drive global growth, operational scale, and expanded access to affordable robotic surgery.Fort Lauderdale, FL, January 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technolog ...

FORT LAUDERDALE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Milan Rao as the Company’s Global Chief Operating Officer and Chief Financial Officer. The Global Chief Operating Officer role is a newly created position. Mr. Rao will succeed Naveen Kumar A ...

Smaller 5-millimeter instruments to be incorporated into the SSi Mantra surgical robotic systemFORT LAUDERDALE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company has completed the development of five new 5-millimeter surgical instruments for clinical use acros ...

Core Viewpoint - SS Innovations has submitted a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, targeting multiple surgical specialties and aiming for U.S. market entry [1][3][5] Company Overview - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [8] - The company is headquartered in India and plans to expand its global presence with cost-effective surgical robotic solutions [8] Product Details - The SSi Mantra surgical robotic system supports various surgical specialties, including general, urological, colorectal, gynecological, and cardiac procedures [2][3] - The system features a modular design with 3 to 5 robotic arms, an ergonomic surgeon command center, a large 3D 4K monitor, and over 40 types of robotic endo-surgical instruments [10] Regulatory Progress - The 510(k) submission is part of the company's strategic plan to introduce the SSi Mantra system to the U.S. market, with the expectation of a review completion within 90 days, although actual approval may take longer [6] - The company is also pursuing EU CE Mark approval, which it anticipates could be obtained in the first half of 2026 [6] Market Presence - As of November 30, 2025, the SSi Mantra has a cumulative installed base of 138 systems across eight countries, with 137 hospitals utilizing the system and over 7,300 surgical procedures performed [6]

Core Viewpoint - SS Innovations International, Inc. has submitted a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, aiming to enhance accessibility and affordability of robotic surgery in the U.S. market [1][2] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies to make robotic surgery accessible to a broader global population [5] - The company is headquartered in India and aims to expand its global presence with cost-effective surgical robotic solutions [5] Product Details - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, an ergonomic command center, and advanced imaging capabilities [6] - It has been clinically validated in India for over 100 different types of surgical procedures [6] Regulatory Progress - The FDA aims to complete reviews of 510(k) submissions within 90 days, although actual approval times may vary [3] - The company is also pursuing CE marking certification in the European Union, expected in the first half of 2026 [3] Market Presence - As of November 30, 2025, the SSi Mantra has a cumulative installed base of 138 systems across eight countries, with 137 hospitals utilizing the system [4] - Over 7,300 surgical procedures have been performed using the SSi Mantra, including 88 telesurgeries and 390 cardiac procedures [4]

Core Insights - SS Innovations has successfully completed the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC), marking a historic milestone in robotic telesurgery [1][4][5] Group 1: Product Overview - The SSi Mantra Tele Surgeon Console is a compact, self-contained, chair-based system designed for telesurgery, allowing operations from various locations, including physician offices [2][4] - The TSC features 3D visualization, magnetic sensor controls, and a smaller footprint compared to traditional operating room setups, enhancing flexibility for surgical experts [7][9] Group 2: Surgical Achievement - Dr. Sudhir Srivastava performed a robotic-assisted coronary artery bypass surgery remotely from New Delhi on a patient located 185 miles away in Jaipur, demonstrating the TSC's capability to extend surgical expertise globally [3][5] Group 3: Company Vision and Future Plans - SS Innovations aims to make robotic surgery affordable and accessible to a broader global population, with plans to expand its presence and technological offerings [8] - The company has refined the TSC since its initial showcase at the Society of Robotic Surgery Meeting in June 2024, indicating ongoing innovation and development [5]

Core Insights - SS Innovations International, Inc. has successfully completed its first telesurgery using the SSi Mantra Tele Surgeon Console (TSC), demonstrating the console's capability to facilitate surgeries from various locations, including physician offices [1][2][3] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [4] - The company is headquartered in India and plans to expand its global presence with user-friendly and cost-effective surgical robotic solutions [4] Product Details - The SSi Mantra Tele Surgeon Console is a compact, self-contained chair-based system that allows for telesurgeries without the need for a full operating room [1][3] - The TSC features inbuilt electronics, lightweight glasses, a magnified 3D view, and magnetic sensor-based controls, making it suitable for remote surgical procedures [3] - The SSi Mantra surgical robotic system includes modular robotic arms, a 3D 4K monitor, and supports over 40 types of robotic endo-surgical instruments for various specialties, including cardiac surgery [5]

Core Insights - SS Innovations International, Inc. reported a significant revenue increase of 192.5% year-over-year, reaching $12.8 million in Q3 2025, primarily driven by higher sales of the SSi Mantra 3 surgical robotic system [1][6][11] Financial Performance - Q3 2025 revenue rose to $12.8 million from $4.4 million in Q3 2024, with a gross profit increase of 166.0% to $6.2 million [6][11] - Gross margin for Q3 2025 was 48.1%, down from 52.8% in Q3 2024 [6] - The net loss for Q3 2025 was $3.7 million, consistent with the net loss of $3.2 million in Q3 2024 [6][11] - For the first nine months of 2025, total revenue increased by 123.0% to $28.0 million compared to $12.5 million in the same period of 2024 [6][8] - Cumulative surgeries performed using the SSi Mantra reached 6,057, including 56 telesurgeries and 319 cardiac procedures [6][12] Business Highlights - The number of SSi Mantra installations in Q3 2025 totaled 27, a 350.0% increase from 6 installations in Q3 2024 [6][11] - The cumulative installed base of SSi Mantra systems reached 127 across seven countries [6][11] - The company has received regulatory approval for the SSi Mantra in seven countries and is preparing to enter the U.S. and European Union markets [4][12] Upcoming Developments - The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025 and aims for CE marking certification in the EU in the first half of 2026 [4][12] - SS Innovations is scheduled to participate in investor conferences in November 2025, providing opportunities for management to engage with investors [9][10]

Core Insights - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [2][5] - The company will participate in upcoming investor conferences, including the UBS Global Healthcare Conference and the Stifel 2025 Healthcare Conference [3][4] Company Overview - SS Innovations is headquartered in India and aims to expand its global presence with cost-effective surgical robotic solutions [5] - The company's product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which support various surgical procedures, including robotic cardiac surgery [5] Product Performance - As of September 30, 2025, the SSi Mantra has a cumulative installed base of 125 systems across six countries, with 119 hospitals having installed the system [6] - Over 6,000 surgical procedures have been performed using the SSi Mantra, including 60 telesurgeries and 310 cardiac procedures [6] Product Features - The SSi Mantra is a modular, multi-arm surgical robotic system featuring advanced technology such as 3 to 5 robotic arms, a 3D 4K monitor, and a virtual real-time image display [7] - It utilizes over 40 different types of robotic endo-surgical instruments and has been clinically validated in India for more than 100 different types of surgical procedures [8]

Core Insights - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to enhance the accessibility and affordability of robotic surgery globally [4][5]. Company Overview - SS Innovations is headquartered in India and aims to expand its global presence with its advanced and cost-effective surgical robotic solutions [4]. - The company’s product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which cater to various surgical procedures, including robotic cardiac surgery [4]. Recent Developments - As of September 30, 2025, the SSi Mantra has a cumulative installed base of 125 systems across six countries, with 119 hospitals utilizing the system [5]. - Over 6,000 surgical procedures have been performed using the SSi Mantra, which includes 60 telesurgeries and 310 cardiac procedures [5]. Upcoming Events - Dr. Sudhir Srivastava and Dr. Vishwa Srivastava will participate in the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025 [2][3]. - The Stifel conference will feature a group presentation at 4:40 p.m. Eastern Time, with a live webcast available on the company’s website [3]. Product Features - The SSi Mantra is a modular, multi-arm surgical robotic system equipped with advanced technology features, including 3 to 5 robotic arms, a 3D 4K monitor, and a virtual real-time imaging capability [6]. - It supports over 40 different types of robotic endo-surgical instruments, validated in more than 100 types of surgical procedures in India [6].